Condition: Genital Psoriasis · Sponsor: Almirall, S.A.
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.
This description comes directly from the study's public registry record.
Senior Director Regional Medical Affairs · +43 0 15953960 · medicalat@almirall.com
Always discuss trial participation with your own doctor first.
| Medizinische Universität Graz | Graz, Styria, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06029257